These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21735240)

  • 1. The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR).
    Nassar K; Lüke J; Lüke M; Kamal M; Abd El-Nabi E; Soliman M; Rohrbach M; Grisanti S
    Graefes Arch Clin Exp Ophthalmol; 2011 Nov; 249(11):1649-60. PubMed ID: 21735240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered Decorin Biology in Proliferative Vitreoretinopathy: A Mechanistic and Cohort Study.
    Begum G; O'Neill J; Chaudhary R; Blachford K; Snead DRJ; Berry M; Scott RAH; Logan A; Blanch RJ
    Invest Ophthalmol Vis Sci; 2018 Oct; 59(12):4929-4936. PubMed ID: 30347087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy.
    Nassar K; Grisanti S; Tura A; Lüke J; Lüke M; Soliman M; Grisanti S
    Exp Eye Res; 2014 Jun; 123():72-86. PubMed ID: 24742493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study.
    Abdullatif AM; Macky TA; Abdullatif MM; Nassar K; Grisanti S; Mortada HA; Soliman MM
    Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2473-2481. PubMed ID: 30128605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY.
    Iglicki M; Zur D; Fung A; Gabrielle PH; Lupidi M; Santos R; Busch C; Rehak M; Cebeci Z; Charles M; Masarwa D; Schwarz S; Barak A; Loewenstein A;
    Acta Diabetol; 2019 Oct; 56(10):1141-1147. PubMed ID: 31089929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.
    Nakagawa M; Refojo MF; Marin JF; Doi M; Tolentino FI
    Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2388-95. PubMed ID: 7591628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal connective tissue growth factor neutralizing antibody or bevacizumab alone or in combination for prevention of proliferative vitreoretinopathy in an experimental model.
    Daftarian N; Baigy O; Suri F; Kanavi MR; Balagholi S; Afsar Aski S; Moghaddasi A; Nourinia R; Abtahi SH; Ahmadieh H
    Exp Eye Res; 2021 Jul; 208():108622. PubMed ID: 34022176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy.
    Tahara YR; Sakamoto TR; Oshima YR; Ishibashi TR; Inomata HR; Murata TR; Hinton DR; Ryan SJ
    Curr Eye Res; 1999 Oct; 19(4):323-9. PubMed ID: 10520228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy.
    Cardillo JA; Farah ME; Mitre J; Morales PH; Costa RA; Melo LA; Kuppermann B; Jorge R; Ashton P
    Br J Ophthalmol; 2004 Sep; 88(9):1201-5. PubMed ID: 15317716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BMP7 antagonizes proliferative vitreoretinopathy through retinal pigment epithelial fibrosis in vivo and in vitro.
    Yao H; Ge T; Zhang Y; Li M; Yang S; Li H; Wang F
    FASEB J; 2019 Mar; 33(3):3212-3224. PubMed ID: 30383450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations.
    Rahimy MH; Peyman GA; Fernandes ML; el-Sayed SH; Luo Q; Borhani H
    J Ocul Pharmacol; 1994; 10(3):561-70. PubMed ID: 7836865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment.
    Zahn G; Volk K; Lewis GP; Vossmeyer D; Stragies R; Heier JS; Daniel PE; Adamis AP; Chapin EA; Fisher SK; Holz FG; Löffler KU; Knolle J
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1028-35. PubMed ID: 19815730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vitrectomy in proliferative vitreoretinopathy. Anatomical and functional results in 501 patients].
    Körner F; Böhnke M
    Klin Monbl Augenheilkd; 1995 Apr; 206(4):239-45. PubMed ID: 7791283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective Effects of Fucoidan on Epithelial-Mesenchymal Transition of Retinal Pigment Epithelial Cells and Progression of Proliferative Vitreoretinopathy.
    Zhang Y; Zhao D; Yang S; Yao H; Li M; Zhao C; Zhang J; Xu GT; Li H; Wang F
    Cell Physiol Biochem; 2018; 46(4):1704-1715. PubMed ID: 29698960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of PVR with a tyrosine kinase inhibitor, dasatinib, in the swine.
    Umazume K; Liu L; Scott PA; de Castro JP; McDonald K; Kaplan HJ; Tamiya S
    Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1150-9. PubMed ID: 23341014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of transforming growth factor β-1 vitreous levels with clinical severity of proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment.
    Palomares-Ordóñez JL; Sánchez-Ramos JA; Ramírez-Estudillo JA; Robles-Contreras A
    Arch Soc Esp Oftalmol (Engl Ed); 2019 Jan; 94(1):12-17. PubMed ID: 30309666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial.
    Schaub F; Hoerster R; Schiller P; Felsch M; Kraus D; Zarrouk M; Kirchhof B; Fauser S
    Trials; 2018 Jul; 19(1):384. PubMed ID: 30012187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy.
    Schiff WM; Hwang JC; Ober MD; Olson JL; Dhrami-Gavazi E; Barile GR; Chang S; Mandava N
    Arch Ophthalmol; 2007 Sep; 125(9):1161-7. PubMed ID: 17846353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EFFICACY OF INTRAVITREAL INJECTION OF BEVACIZUMAB IN VITRECTOMY FOR PATIENTS WITH PROLIFERATIVE VITREORETINOPATHY RETINAL DETACHMENT: A Meta-analysis of Prospective Studies.
    Zhao XY; Xia S; Wang EQ; Chen YX
    Retina; 2018 Mar; 38(3):462-470. PubMed ID: 28272285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of perfluorocarbon liquids, silicone oil, and 5-fluorouracil in the management of experimental PVR.
    Hegazy HM; Peyman GA; Liang C; Unal MH; Molinari LC; Kazi AA
    Int Ophthalmol; 1998-1999; 22(4):239-46. PubMed ID: 10674869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.